101 related articles for article (PubMed ID: 2308919)
1. Assessment of proliferative rate of breast cancer by Ki-67 monoclonal antibody.
Marchetti E; Querzoli P; Marzola A; Bagni A; Ferretti S; Fabris G; Nenci I
Mod Pathol; 1990 Jan; 3(1):31-5. PubMed ID: 2308919
[TBL] [Abstract][Full Text] [Related]
2. Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction.
Domagala W; Lasota J; Bartkowiak J; Weber K; Osborn M
Am J Pathol; 1990 Jan; 136(1):219-27. PubMed ID: 2153347
[TBL] [Abstract][Full Text] [Related]
3. [The immunohistochemical growth fraction (Ki-67) of breast cancers: relations to tumor spread, tumor morphology and receptor testing].
Weikel W; Beck T; Rosenthal H; Herzog R
Geburtshilfe Frauenheilkd; 1989 Mar; 49(3):277-82. PubMed ID: 2566552
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of estrogen and progesterone receptors performed with an antigen-retrieval technique on methacarn-fixed paraffin-embedded breast cancer tissues.
Oyaizu T; Arita S; Hatano T; Tsubura A
J Surg Res; 1996 Jan; 60(1):69-73. PubMed ID: 8592434
[TBL] [Abstract][Full Text] [Related]
5. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer.
Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; van de Vijver MJ
Eur J Surg Oncol; 1999 Aug; 25(4):356-63. PubMed ID: 10419704
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers.
Rosa FE; Caldeira JR; Felipes J; Bertonha FB; Quevedo FC; Domingues MA; Moraes Neto FA; Rogatto SR
Hum Pathol; 2008 May; 39(5):720-30. PubMed ID: 18234277
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two antibodies for evaluation of estrogen receptors in paraffin-embedded tumors.
Hendricks JB; Wilkinson EJ
Mod Pathol; 1993 Nov; 6(6):765-70. PubMed ID: 7508117
[TBL] [Abstract][Full Text] [Related]
8. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
9. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints.
Jalava P; Kuopio T; Huovinen R; Laine J; Collan Y
Anticancer Res; 2005; 25(3c):2535-42. PubMed ID: 16080489
[TBL] [Abstract][Full Text] [Related]
11. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
12. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
14. Proliferative activity and steroid receptors determined by immunohistochemistry in adjacent frozen sections of 102 breast carcinomas.
Helin ML; Helle MJ; Helin HJ; Isola JJ
Arch Pathol Lab Med; 1989 Aug; 113(8):854-7. PubMed ID: 2667495
[TBL] [Abstract][Full Text] [Related]
15. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival.
Isola J; Kallioniemi OP; Korte JM; Wahlström T; Aine R; Helle M; Helin H
J Pathol; 1990 Dec; 162(4):295-301. PubMed ID: 2290114
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC).
Beck T; Weikel W; Brumm C; Wilkens C; Pollow K; Knapstein PG
Gynecol Oncol; 1994 May; 53(2):220-7. PubMed ID: 8188083
[TBL] [Abstract][Full Text] [Related]
17. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
Spyratos F; Ferrero-Poüs M; Trassard M; Hacène K; Phillips E; Tubiana-Hulin M; Le Doussal V
Cancer; 2002 Apr; 94(8):2151-9. PubMed ID: 12001111
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols.
Foekens JA; Portengen H; van Putten WL; Peters HA; Krijnen HL; Alexieva-Figusch J; Klijn JG
Cancer Res; 1989 Nov; 49(21):5823-8. PubMed ID: 2676151
[TBL] [Abstract][Full Text] [Related]
19. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
Lumachi F; Basso SM; Brandes AA; Pagano D; Ermani M
Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen value as a marker in breast cancer.
Narita D; Cimpean AM; Anghel A; Raica M
Neoplasma; 2006; 53(2):161-7. PubMed ID: 16575473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]